Certified by Founder
Lodge
LoQus23 Therapeutics Ltd
start up
United Kingdom
- Cambridge, Cambridgeshire
- 02/10/2024
- Series A
- $46,550,175
LoQus23 are discovering oral small molecule therapies targeting aberrant DNA mismatch repair to effectively treat Huntington’s and other triplet repeat diseases.
- Industry Biotechnology Research
- Website https://loqus23.com/
- LinkedIn https://www.linkedin.com/company/loqus23-therapeutics-ltd/
NuCube Energy | $13,000,000 | (Feb 20, 2026)
Vizzia | $35,300,400 | (Feb 20, 2026)
PolyGone Systems Inc | $4,000,000 | (Feb 20, 2026)
Altesa BioSciences, Inc. | $75,000,000 | (Feb 20, 2026)
Eagle Wireless | $30,000,000 | (Feb 20, 2026)
Stacks | $23,000,000 | (Feb 20, 2026)
SPRX | $31,000,000 | (Feb 20, 2026)
Adronite | $5,000,000 | (Feb 20, 2026)
Odynn | $9,500,000 | (Feb 20, 2026)
Ascent(US) | $45,000,000 | (Feb 20, 2026)
Ownwell | $50,000,000 | (Feb 20, 2026)
Badge | $17,100,000 | (Feb 20, 2026)